RE:The time arrived 15 years ago, but the "rewards" just now? A LOT of tributaries have formed on the back of the le$$ than raging rivers that have formed on the banks of the smallest Great lake buy size, but 2nd smallest buy volume.....
Hard to imagine how CTSO got to $15.24 USD with ALL those German salesforce issues, or how Aethlon and Sigy have pushed ahead...
2007, was 15 years AGO..Bear in MIND, twas August 22 2014 when the FDA said NO more Spectral or Meddwell for those within an "arm's length"...Bear in mind again, the interim data had ALREADY come out..well "sort of" (
3 NR's and little to know detail ) BUT the absolute efficacy was 11% to 12% - though not printed, this was CONFIRMED by Spectral AND the number of patients chosen buy the
FDA Hmmmmmm?? ..i wonder what is taking SO LONG?
NOT knowing the capacity of the PMX filter, NOT following the phase 2 Euphas lead, BAD mojo from Natalie at Reuters...Buoy, was she ever WRONG! Phase 3 forms a 75% weighting for current phase 3B confirmatory..
.INDEED..things take time, long term..and 100 MILLION share later....precision medicine meets precision investing! Comment
doi: 10.1186/cc5918. A targeted extracorporeal therapy for endotoxemia: the time has come
Affiliations
Free PMC article Abstract
Endotoxemia, whether primary (due to Gram-negative infection) or secondary (due to epithelial barrier dysfunction), appears to be extremely common in the critically ill and injured. High levels of endotoxin activity are associated with worse clinical outcomes. In Japan, polymyxin B hemoperfusion has been available to treat endotoxemia for more than ten years. Multiple small trials, often limited by methodological quality, show that polymyxin B hemo-perfusion may have favorable effects on survival and hemodynamics. Further study of this therapy would seem justified.